Key Highlights

  • Lockheed Martin (NYSE:LMT) gained 5.13% on October 26, 2026 after Morgan Stanley upgraded it to Overweight with a USD 835 target, though one account showed a smaller gain of about 3%.
  • Moderna (NASDAQ:MRNA) fell 7.23% premarket even though Phase 3 melanoma data with Merck showed a hazard ratio of 0.58, and the data and release were dated October 22, 2026 in published market data.
  • Genmab (NASDAQ:GMAB) jumped 12% in European trading on a positive late-stage trial update, while the trial name, the results and the move in the US-listed receipt were not available in published market data.
  • Eledon Pharmaceuticals (NASDAQ:ELDN) faces a short seller report dated October 23 that claims it is cash-strapped ahead of a 620-patient Phase 3, and these allegations were not checked independently in published market data.

Lockheed Martin (NYSE:LMT): Morgan Stanley Upgrade

On Monday, October 26, 2026, Lockheed Martin (NYSE:LMT) gained 5.13% after Morgan Stanley raised its rating to Overweight with a target of USD 835, according to one set of closing quotes. A different account showed a gain of about 3%, so the figure differs by source and time of day. An Overweight rating means the analyst expects the stock to outperform its peer group over the next year. A price target is the analyst's estimate of fair value in twelve months, not a prediction that the price will reach it. The analyst's reasons were not available for this article, and the previous rating was not stated. Defence and government-services names rose together. CACI International (NYSE:CACI) gained 4.89% after Jefferies assigned a Buy rating. Booz Allen Hamilton (NYSE:BAH) gained 6.44% after TD Cowen assigned a Buy rating with a target of USD 95. One account has CACI gaining about 6%, so those figures also differ by source. The group move suggests that sector flows, and not only company news, helped lift the three stocks.

Moderna (NASDAQ:MRNA): Cancer Vaccine Data and a Fall

Moderna (NASDAQ:MRNA) and Merck reported Phase 3 results from the INTerpath-001 trial of an individualized neoantigen therapy, a personalized cancer vaccine, in melanoma. The trial showed a recurrence-free survival hazard ratio of 0.58 and a distant metastasis-free survival hazard ratio of 0.62. The company release was dated October 22, 2026, and Merck shares moved 1.1% lower that day, yet the 7.23% fall for Moderna is dated October 26 in published market data. Because the data were already public by then, the Monday decline is not explained by new trial information, and the specific cause was not available for this article. Moderna's partner Merck is a much larger company, so its shares reacted less to the same news. A hazard ratio compares the rate of events, here cancer recurrence or death, in the treated group with the rate in the comparison group over time. A ratio of 0.58 means the treated group had about 42% fewer events at any given moment, a relative reduction and not an absolute one. A ratio of 0.62 for distant metastasis-free survival means a 38% lower relative risk of cancer spreading, simple arithmetic. The results were presented as a late-breaker at the European Society for Medical Oncology congress and published in the New England Journal of Medicine. Investors sometimes sell after good data when the result was widely expected, a pattern known as selling the news.

Genmab (NASDAQ:GMAB): Late-Stage Trial Update

Genmab, a biotechnology company based in Denmark, saw its shares rise 12% in European trading on Monday, October 26, 2026 after a positive update from a late-stage trial, according to published market data. A late-stage trial, usually Phase 3, tests a treatment in a large group of patients and is the last major step before regulatory submission. The information available for this article did not name the trial or give the results, such as survival or response rates, so no clinical figure is stated here. Genmab (NASDAQ:GMAB) trades in the United States as an American depositary receipt, and the US move was not available. The company is known for antibody-based cancer medicines and partnerships with larger drug makers. An American depositary receipt is a certificate that represents shares of a foreign company and trades on a US exchange in dollars. If the news came after the European close or before the US open, the US shares could react differently. Biotech investors usually look at the primary endpoint, safety, the comparison group and the timing of regulatory filings. The headline number is often only part of the story, so analysts read the full data once they are published.

Eledon Pharmaceuticals (NASDAQ:ELDN): Short Seller Report

A short seller published a report on October 23, 2026, and its claims were still being discussed on October 26. According to the report, Eledon Pharmaceuticals (NASDAQ:ELDN) lacks enough cash to fund a 620-patient Phase 3 trial and will need to sell equity within 60 to 90 days. The report cites going-concern language and an at-the-market facility of USD 75 million. These are allegations. The company's response and its latest cash balance were not available for this article, and the claims were not independently checked. A reader should check the cash figure, the quarterly burn rate and the facility terms in the company's SEC filings. Cash runway is the number of months a company can operate before it needs funding, and it is the central test of the allegation. Going-concern language is a statement in a company's financial statements that management or auditors see substantial doubt about its ability to continue operating for at least twelve months without new funding. An at-the-market facility lets a company sell shares gradually into the open market through a broker, at prevailing prices, up to a stated amount. Each sale adds shares and dilutes existing holders, so a stock can fall even when a trial goes well. A USD 75 million facility gives flexibility but also means that new shares can reach the market without a fixed announcement date.

Where Things Stand

The answer is that an analyst upgrade lifted Lockheed Martin (NYSE:LMT), while three healthcare stories pulled in different directions: a fall at Moderna despite strong data, a jump at Genmab and an allegation at Eledon Pharmaceuticals. Several details were not available. Regulatory plans, full trial data and company filings are the next tests. Next filings from Lockheed Martin (NYSE:LMT) will add detail. Fresh disclosure from Moderna (NASDAQ:MRNA) is the next test. Official notices from Genmab (NASDAQ:GMAB) remain the best guide. Further company updates from Eledon Pharmaceuticals (NASDAQ:ELDN) are awaited. Further disclosure from Moderna (NASDAQ:MRNA) would clarify the picture. Official notices from Genmab (NASDAQ:GMAB) remain the best guide.